The UK medical device regulatory landscape is entering a period of significant change. Through the introduction of the Pre-Market Statutory Instrument (SI), the Medicines and Healthcare products Regulatory Agency (MHRA) aims to modernise the regulatory framework, improve patient access to innovative technologies and strengthen the UK’s position as an attractive market for MedTech innovation.
For manufacturers, these reforms present both opportunities and challenges. New pathways could accelerate market access for products already approved in trusted international jurisdictions, while enhanced requirements around traceability, technical documentation and post-market oversight will increase regulatory responsibilities. Understanding these changes now is essential for manufacturers planning future product launches and long-term regulatory strategies.
Why the UK Is Reforming Medical Device Regulation
The UK government’s stated objective is to provide faster access to safe and innovative medical devices while supporting economic growth and encouraging investment within the UK MedTech sector.
Since leaving the European Union, the UK has had the opportunity to develop a more flexible and internationally aligned regulatory framework. Rather than creating an entirely separate system, the reforms seek to combine strong patient protections with mechanisms that reduce unnecessary regulatory barriers for manufacturers.
The result is a framework designed to improve innovation, support patient access and strengthen the competitiveness of the UK market.Since leaving the European Union, the UK has had the opportunity to review its regulatory framework and consider how it can better align with international regulatory principles while maintaining high standards of patient safety. Rather than creating an entirely separate system, the proposed reforms aim to balance robust oversight with more proportionate regulatory requirements for manufacturers.
The reforms are intended to support innovation, improve patient access to new technologies and enhance the attractiveness of the UK market for medical device manufacturers.
The International Reliance Pathway
One of the most significant changes introduced through the Pre-Market SI is the International Reliance Pathway. This framework is intended to allow certain devices already approved in trusted jurisdictions, including the United States, Canada and Australia, to access the UK market more efficiently. Historically, many manufacturers prioritised the United States and European Union before considering UK market entry. Regulatory requirements often meant that the UK became a later-stage launch market despite its importance.
The International Reliance Pathway has the potential to change this dynamic. By leveraging approvals from recognised international regulators, manufacturers may be able to reduce duplication of regulatory effort and accelerate access to UK patients. For companies already pursuing FDA clearance or approvals in Canada and Australia, the UK could become a much more attractive second-launch market than it has been previously.
How Launch Strategies May Change
Launch sequencing remains a critical strategic decision for medical device companies.
Traditionally, manufacturers have often focused on obtaining FDA clearance or CE marking before expanding into additional markets. Regulatory complexity and resource constraints frequently meant that smaller jurisdictions were addressed later.
If the International Reliance Pathway operates as intended, some manufacturers may begin considering UK market entry sooner following approval in a recognised reliance jurisdiction. This could potentially shorten the route to commercialisation and increase access to UK healthcare providers and patients. For start-ups and growing MedTech companies, the pathway may offer an opportunity to expand internationally with greater efficiency.
Mandatory UDI Requirements
One of the most significant changes is the introduction of mandatory Unique Device Identifier (UDI) requirements. UDI systems improve traceability by assigning unique identifiers to medical devices throughout their lifecycle. These identifiers help regulators, healthcare providers and manufacturers track products more effectively and respond more efficiently to safety concerns.
Manufacturers are likely to need to review labelling processes, internal databases and traceability procedures to ensure compliance. Although implementation may require additional investment and operational changes, improved traceability is expected to support patient safety and strengthen post-market surveillance activities.
New Implant Card Requirements
The reforms also introduce new obligations for implantable medical devices.
Healthcare organisations that implant certain devices will be required to provide patients with implant cards containing key information about the implanted device. The intention is to improve transparency and support more effective management of safety communications, adverse events and product recalls.
For manufacturers, this may require updates to labelling, documentation and information management processes to ensure accurate information is available throughout the supply chain.
Alignment of IVD Classification Rules
Another major area of reform relates to in vitro diagnostic (IVD) devices.
The UK intends to align IVD classification rules more closely with International Medical Device Regulators Forum (IMDRF) principles through the introduction of a classification structure based on Classes A, B, C and D. This approach will be familiar to many manufacturers already operating under international regulatory frameworks.
While alignment will not eliminate all regulatory differences between jurisdictions, it may improve consistency in risk classification approaches and support more efficient global regulatory planning.
Stronger Support for Software and AI Medical Devices
Digital health technologies and artificial intelligence continue to play an increasingly important role in healthcare delivery.
Recognising this, the proposed reforms include provisions specifically designed to address software and AI-based medical devices. One of the most notable concepts is the introduction of Predetermined Change Control Plans (PCCPs).
PCCPs are intended to provide a framework through which certain pre-defined software changes may be managed without requiring a full regulatory submission for every update. For developers of software and AI technologies, this could offer greater flexibility while maintaining appropriate regulatory oversight.
However, organisations will still require robust lifecycle management processes, effective change control procedures and comprehensive technical documentation to support these approaches..
Higher Standards for Evidence and Documentation
The proposed framework introduces stronger expectations around evidence generation, technical documentation, traceability and post-market surveillance. Manufacturers will need to demonstrate clear alignment between intended purpose statements, product claims and supporting evidence.
Documentation retention requirements are also being strengthened to help ensure that important information remains available throughout the product lifecycle. These measures are intended to enhance confidence in UK-approved technologies and strengthen patient protection.
For organisations with mature quality management systems, many of these requirements may already align with existing regulatory best practice. Smaller companies and start-ups, however, may need to invest further in compliance infrastructure and regulatory processes.
Custom-Made Device Requirements
Proposed changes focus on improving traceability, record-keeping and regulatory oversight for custom-made products. As healthcare systems continue to become more digitalised, manufacturers operating in this area should review existing processes to ensure they remain aligned with evolving regulatory expectations.
Greater International Alignment
Rather than developing a uniquely UK-specific framework, the proposed changes move closer to internationally recognised regulatory principles and standards. This may help manufacturers develop more efficient global regulatory strategies while reducing some of the complexity associated with managing multiple regulatory systems.
Although significant differences between jurisdictions will remain, greater alignment with international best practice could support improved consistency and operational efficiency for globally active manufacturers.
What Manufacturers Should Do Now
The details of the reforms will continue to develop as implementation progresses, so manufacturers should keep a close eye on regulatory updates and forthcoming MHRA guidance. Understanding how these changes may affect market access, compliance requirements and future product strategies will be key to staying ahead of the curve.
LFH helps medical device and IVD manufacturers navigate evolving UK regulatory requirements, from market access strategies and international reliance pathways to technical documentation, quality systems and post-market compliance. Our team supports organisations in preparing for regulatory change while maintaining efficient routes to market and long-term commercial success.
FAQs – Pre-Market SI
What is the UK Pre-Market SI?
The Pre-Market Statutory Instrument is a regulatory reform package designed to modernise UK medical device regulation and improve patient access to innovative technologies.
What is the International Reliance Pathway?
It is a framework that may allow devices approved in trusted jurisdictions such as the United States, Canada and Australia to access the UK market more efficiently.
Will UDI become mandatory in the UK?
Yes, the reforms introduce compulsory Unique Device Identifier requirements to improve device traceability.
How will the reforms affect IVD manufacturers?
IVD classifications will align with IMDRF principles using a Class A, B, C and D structure.
What are Predetermined Change Control Plans?
PCCPs are regulatory mechanisms that may allow certain software and AI updates to occur without repeated regulatory submissions, provided approved controls are in place.
Will regulatory requirements become easier overall?
Some market access pathways may become faster, but evidence, documentation, traceability and post-market obligations will generally become more rigorous.
